Retatrutide

Explore one of the most closely watched multi-receptor compounds in modern metabolic research, designed to help investigators study three complementary signaling pathways in a single molecule.

Primary research pathwaysGIP · GLP-1 · Glucagon

In simple termsAppetite, blood-sugar signaling, metabolism, and body-weight research.

Scientific overview

What is Retatrutide?

Retatrutide is a synthetic investigational peptide designed to activate three metabolic hormone receptors: GIP, GLP-1, and glucagon. This multi-receptor design is being studied for effects on appetite regulation, glucose control, energy expenditure, and body weight in defined clinical-trial populations.

Mechanism under study

How researchers examine it

GLP-1 and GIP receptor activity can influence glucose-dependent insulin signaling and appetite, while glucagon-receptor activity can affect hepatic and energy-metabolism pathways. The balance among these signals—and the safety of sustained activation—remains under clinical investigation.

Evidence landscape

What the research currently shows

A randomized phase 2 obesity trial reported dose-dependent group-level changes in body weight. Phase 3 studies are ongoing; retatrutide remains investigational and trial findings do not establish outcomes for research materials sold outside a clinical trial.

Research focus

Why it stands out

A single investigational molecule designed to engage three complementary metabolic receptors.
Studied across appetite, glucose-signaling, energy-expenditure, and body-weight pathways.
One of the most closely followed compounds in current multi-receptor metabolic research.

Primary references

Phase 2 trial · PubMed Phase 3 study · ClinicalTrials.gov

Continue exploring

Return to the research catalog.

View all compounds